Journal
FLUIDS AND BARRIERS OF THE CNS
Volume 13, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12987-016-0025-2
Keywords
Brain; Cerebrospinal fluid; Clinical trials; Diuretic; Drug therapy; Fibrinolysis; Hydrocephalus; Inflammation; Intracranial hemorrhage; Neuroprotective
Categories
Funding
- Canadian Institutes of Health Research
- Research Manitoba
Ask authors/readers for more resources
Pharmacological interventions have been tested experimentally and clinically to prevent hydrocephalus and avoid the need for shunting beginning in the 1950s. Clinical trials of varied quality have not demonstrated lasting and convincing protective effects through manipulation of cerebrospinal fluid production, diuresis, blood clot fibrinolysis, or manipulation of fibrosis in the subarachnoid compartment, although there remains some promise in the latter areas. Acetazolamide bolus seems to be useful for predicting shunt response in adults with hydrocephalus. Neuroprotection in the situation of established hydrocephalus has been tested experimentally beginning more recently. Therapies designed to modify blood flow or pulsation, reduce inflammation, reduce oxidative damage, or protect neurons are so far of limited success; more experimental work is needed in these areas. As has been recommended for preclinical studies in stroke and brain trauma, stringent conditions should be met for preclinical studies in hydrocephalus.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available